Group A streptococcal vaccines: Paving a path for accelerated development

Vaccine

Volumn 31, Issue SUPPL2, 2013, Pages

  Dale, James B ^a   Fischetti, Vincent A ^b   Carapetis, Jonathan R ^c   Steer, Andrew C ^d   Sow, Samba ^e   Kumar, Rajesh ^f   Mayosi, Bongani M ^g   Rubin, Fran A ^h   Mulholland, Kim ⁱ   Hombach, Joachim Maria ^j   Schödel, Florian ^k   Henao Restrepo, Ana Maria ^j  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Center for Vaccine Development Mali   (Mali)

^f POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h Bethesda ^*  (United States)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j WORLD HEALTH ORGANIZATION   (Switzerland)

^k Philimmune LLC   (United States)

more..

Author keywords

Group A streptococci; Rheumatic heart disease; Vaccines

Indexed keywords

STREPTOCOCCUS GROUP A VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACUTE POST STREPTOCOCCAL GLOMERULONEPHRITIS; DRUG SAFETY; GLOMERULONEPHRITIS; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE;

ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BIOMEDICAL RESEARCH; CARRIER PROTEINS; COST OF ILLNESS; HUMANS; MOLECULAR EPIDEMIOLOGY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 84876704846     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.045     Document Type: Review

References (64)

1. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5(11):685-694.
2. Michaud C., Rammohan R., Narula J. Cost-effectiveness analysis of intervention strategies for reduction of the burden of rheumatic heart disease. Rheumatic Fever 1999, 485-497. American Registry of Pathology, Washington, DC. Narula Jea (Ed.).
3. Steer A.C., Lamagni T., Curtis N., Carapetis J.R. Invasive group a streptococcal disease: epidemiology, pathogenesis and management. Drugs 2012, 72(9):1213-1227.
4. Marijon E., Ou P., Celermajer D.S., Ferreira B., Mocumbi A.O., Jani D., et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007, 357(5):470-476.
5. Paar J.A., Berrios N.M., Rose J.D., Caceres M., Pena R., Perez W., et al. Prevalence of rheumatic heart disease in children and young adults in Nicaragua. Am J Card 2010, 105(12):1809-1814.
6. Beaton A., Okello E., Lwabi P., Mondo C., McCarter R., Sable C. Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren. Circulation 2012, 125(25):3127-3132.
7. Standardized protocols for GAS burden estimation. Available from: [cited 05.09.2012]. http://www.niaid.nih.gov/TOPICS/STREPTOCOCCAL/Pages/protocols.aspx.
8. Remenyi B., Wilson N., Steer A., Ferreira B., Kado J., Kumar K., et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease-an evidence-based guideline. Nat Rev 2012, 9(5):297-309.
9. Marijon E., Celermajer D.S., Tafflet M., El-Haou S., Jani D.N., Ferreira B., et al. Rheumatic heart disease screening by echocardiography: the inadequacy of world health organization criteria for optimizing the diagnosis of subclinical disease. Circulation 2009, 120(8):663-668.
10. CDC Streptococcus Laboratory. Available from: [cited 05.09.2012]. http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm.
11. Hilleman Laboratories meeting summary: is a group A streptococcal vaccine desirable and feasible, New Delhi, March 2010. Available from: ; 2011 [cited 05.06.2012]. http://www.hillemanlabs.org/pdf/gas-meeting-summary.pdf.
12. Proceedings of the tenth global vaccine research forum and parallel satellite symposia, Geneva, 26-29 June 2011. Available from: ; 2012 [cited 25.05.2012]. http://www.who.int/immunization/documents/innovation/WHO_IVB_12.06/en/index.html.
13. Kotloff K.L., Dale J.B. Progress in group A streptococcal vaccine development. Pediatr Infect Dis J 2004, 23(8):765-766.
14. Massell B.F., Michael J.G., Amezcua J., Siner M. Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol 1968, 16(3):509-518.
15. Massell B.F., Honikman L.H., Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969, 207(6):1115-1119.
16. Kotloff K.L., Corretti M., Palmer K., Campbell J.D., Reddish M.A., Hu M.C., et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004, 292(6):709-715.
17. McNeil S.A., Halperin S.A., Langley J.M., Smith B., Warren A., Sharratt G.P., et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005, 41(8):1114-1122.
18. McNeil S., Halperin S., Langley J.M., Smith B., Baxendale D.M., Warren A., et al. A double-blind, randomized, phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults. Int Congr Ser 2005, 1289:303-306.
19. Dale J.B., Penfound T.A., Chiang E.Y., Walton W.J. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 2011, 29(46):8175-8178.
20. O'Loughlin R.E., Roberson A., Cieslak P.R., Lynfield R., Gershman K., Craig A., et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007, 45(7):853-862.
21. Luca-Harari B., Darenberg J., Neal S., Siljander T., Strakova L., Tanna A., et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2009, 47(4):1155-1165.
22. Lamagni T.L., Darenberg J., Luca-Harari B., Siljander T., Efstratiou A., Henriques-Normark B., et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008, 46(7):2359-2367.
23. Jackson S.J., Steer A.C., Campbell H. Systematic review: estimation of global burden of non-suppurative sequelae of upper respiratory tract infection: rheumatic fever and post-streptococcal glomerulonephritis. Trop Med Int Health 2011, 16(1):2-11.
24. Hoy W.E., White A.V., Dowling A., Sharma S.K., Bloomfield H., Tipiloura B.T., et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney Int 2012, 81(10):1026-1032.
25. Steer A.C., Law I., Matatolu L., Beall B.W., Carapetis J.R. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009, 9(10):611-616.
26. Bessen D.E., Carapetis J.R., Beall B., Katz R., Hibble M., Currie B.J., et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis 2000, 182(4):1109-1116.
27. Hu M., Walls M., Stroop S., Reddish M., Beall B., Dale J. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002, 70:2171-2177.
28. Smeesters P.R., Mardulyn P., Vergison A., Leplae R., Van Melderen L. Genetic diversity of group A streptococcus M protein: implications for typing and vaccine development. Vaccine 2008, 26(46):5835-5842.
29. Steer A.C., Magor G., Jenney A.W., Kado J., Good M.F., McMillan D., et al. emm and C-repeat region molecular typing of beta-hemolytic streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009, 47(8):2502-2509.
30. Shulman S.T., Tanz R.R., Dale J.B., Beall B., Kabat W., Kabat K., et al. Seven-year surveillance of North American pediatric group a streptococcal pharyngitis isolates. Clin Infect Dis 2009, 49(1):78-84.
31. Bessen D., Fischetti V.A. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun 1988, 56:2666-2672.
32. Bronze M.S., Courtney H.S., Dale J.B. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. J Immunol 1992, 148:888-893.
33. Batzloff M., Yan H., Davies M., Hartas J., Good M. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res 2004, 119Suppl:104-107.
34. Batzloff M.R., Hayman W.A., Davies M.R., Zeng M., Pruksakorn S., Brandt E.R., et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003, 187(10):1598-1608.
35. Penfound T., Chiang E., Ahmed E., Dale J. Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. Vaccine 2010, 28(31):5017-5022.
36. Carapetis J.R., Zuhlke L.J. Global research priorities in rheumatic fever and rheumatic heart disease. Ann Pediat Cardiol 2011, 4(1):4-12.
37. Severin A., Nickbarg E., Wooters J., Quazi S.A., Matsuka Y.V., Murphy E., et al. Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins. J Bacteriol 2007, 189(5):1514-1522.
38. Rodriguez-Ortega M.J., Norais N., Bensi G., Liberatori S., Capo S., Mora M., et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006, 24(2):191-197.
39. Fritzer A., Senn B.M., Minh D.B., Hanner M., Gelbmann D., Noiges B., et al. Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine. Infect Immun 2010, 78(9):4051-4067.
40. Cleary P.P., Prahbu U., Dale J.B., Wexler D.E., Handley J. Streptococcal C5a peptidase is a highly specific endopeptidase. Infect Immun 1992, 60:5219.
41. Hasty D.L., Ofek I., Courtney H.S., Doyle R.J. Multiple adhesins of streptococci. Infect Immun 1992, 60:2147-2152.
42. Steer A.C., Jenney A.W., Kado J., Good M.F., Batzloff M., Magor G., et al. Prospective surveillance of streptococcal sore throat in a tropical country. Pediatr Infect Dis J 2009, 28(6):477-482.
43. McArthur J., Medina E., Mueller A., Chin J., Currie B.J., Sriprakash K.S., et al. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model. Infect Immun 2004, 72(12):7342-7345.
44. Currie B.J. Group A streptococcal infections of the skin: molecular advances but limited therapeutic progress. Curr Opin Infect Dis 2006, 19(2):132-138.
45. Parks T., Smeesters P.R., Steer A.C. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis 2012, 25(2):145-153.
46. Sixty-fifth World Health Assembly. Available from: [cited 05.09.2012]. http://www.who.int/mediacentre/events/2012/wha65/en/index.html.
47. Guilherme L., Postol E., Freschi de Barros S., Higa F., Alencar R., Lastre M., et al. A vaccine against S. pyogenes: design and experimental immune response. Methods 2009, 49(4):316-321.
48. Bauer M.J., Georgousakis M.M., Vu T., Henningham A., Hofmann A., Rettel M., et al. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. Vaccine 2012, 30(12):2197-2205.
49. Sabharwal H., Michon F., Nelson D., Dong W., Fuchs K., Manjarrez R.C., et al. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis 2006, 193(1):129-135.
50. Dale J.B., Chiang E.Y., Liu S.Y., Courtney H.S., Hasty D.L. New protective antigen of group A streptococci. J Clin Invest 1999, 103:1261-1268.
51. Shet A., Kaplan E.L., Johnson D.R., Cleary P.P. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis 2003, 188(6):809-817.
52. Kawabata S., Kunitomo E., Terao Y., Nakagawa I., Kikuchi K., Totsuka K., et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun 2001, 69(2):924-930.
53. Courtney H.S., Hasty D.L., Dale J.B. Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect Immun 2003, 71(9):5097-5103.
54. Schulze K., Medina E., Guzman C.A. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain. Vaccine 2006, 24(9):1446-1450.
55. Kapur V., Maffei J.T., Greer R.S., Li L.L., Adams G.J., Musser J.M. Vaccination with streptococcal extracellular cysteine protease (interleukin 1B convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathogen 1994, 16:443.
56. McCormick J.K., Tripp T.J., Olmsted S.B., Matsuka Y.V., Gahr P.J., Ohlendorf D.H., et al. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J Immunol 2000, 165(4):2306-2312.
57. Koller T., Manetti A.G., Kreikemeyer B., Lembke C., Margarit I., Grandi G., et al. Typing of the pilus-protein-encoding FCT region and biofilm formation as novel parameters in epidemiological investigations of Streptococcus pyogenes isolates from various infection sites. J Med Microbiol 2011, 59(Pt 4):442-452.
58. Zingaretti C., Falugi F., Nardi-Dei V., Pietrocola G., Mariani M., Liberatori S., et al. Streptococcus pyogenes SpyCEP: a chemokine-inactivating protease with unique structural and biochemical features. FASEB J 2010.
59. Liu M., Zhu H., Zhang J., Lei B. Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci. Infect Immun 2007, 75(7):3651-3657.
60. Grandi G, Telford JL, Bensi G, inventors; Novartis Vaccines and Diagnostics, SRL, assignee. Immunogenic compositions for Streptococcus pyogenes. US. 2010.
61. McMillan D.J., Batzloff M.R., Browning C.L., Davies M.R., Good M.F., Sriprakash K.S., et al. Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 2004, 22(21-22):2783-2790.
62. McMillan D.J., Davies M.R., Browning C.L., Good M.F., Sriprakash K.S. Prospecting for new group A streptococcal vaccine candidates. Indian J Med Res 2004, 119(Suppl.):121-125.
63. Lei B., Liu M., Chesney G.L., Musser J.M. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. J Infect Dis 2004, 189(1):79-89.
64. Kotloff K.L., Wasserman S.S., Jones K.F., Livio S., Hruby D.E., Franke C.A., et al. Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine. Infect Immun 2005, 73(4):2360-2366.